For patients with mild age-related diabetes (MARD) who are characterised by moderate insulin resistance and mild insulin deficiency, older age at the time of diagnosis, and lower risk of developing end-organ damage, sulfonylurea and DPP-4 inhibitors could be the best options as additional therapies if metformin treatment alone cannot control glucose. This evidence concerns the gene DPP4 and Insulin resistance.